{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T07:42:18Z","timestamp":1792568538187,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100018736","name":"Kaken Pharmaceutical","doi-asserted-by":"publisher","award":["24K12260"],"award-info":[{"award-number":["24K12260"]}],"id":[{"id":"10.13039\/100018736","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"DOI":"10.1007\/s40120-026-01049-0","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T07:12:33Z","timestamp":1792566753000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Effectiveness and Tolerability of Rimegepant as Second- or Third-Line Acute Treatment for Migraine: A Prospective Observational Study"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9251-4230","authenticated-orcid":false,"given":"Takafumi","family":"Tanei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9675-7395","authenticated-orcid":false,"given":"Satoshi","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0895-5667","authenticated-orcid":false,"given":"Shun","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4225-110X","authenticated-orcid":false,"given":"Shinsuke","family":"Muraoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5346-6451","authenticated-orcid":false,"given":"Tomotaka","family":"Ishizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3086-4666","authenticated-orcid":false,"given":"Takahiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9237-1911","authenticated-orcid":false,"given":"Satoshi","family":"Shinoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5254-2088","authenticated-orcid":false,"given":"Toshihiko","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2484-1360","authenticated-orcid":false,"given":"Ryuta","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"key":"1049_CR1","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1080\/03007995.2021.1971179","volume":"37","author":"K Hirata","year":"2021","unstructured":"Hirata K, Ueda K, Komori M, et al. Comprehensive population-based survey of migraine in Japan: results of the ObserVational Survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) study. Curr Med Res Opin. 2021;37:1945\u201355.","journal-title":"Curr Med Res Opin"},{"key":"1049_CR2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s10194-021-01243-5","volume":"22","author":"T Shimizu","year":"2021","unstructured":"Shimizu T, Sakai F, Miyake H, et al. Disability, quality of life, productivity impairment and employer costs of migraine in the workplace. J Headache Pain. 2021;22:29.","journal-title":"J Headache Pain"},{"issue":"Suppl 1","key":"1049_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1046\/j.1526-4610.2002.0420s1010.x","volume":"42","author":"J Pascual","year":"2002","unstructured":"Pascual J. Clinical benefits of early triptan therapy for migraine. Headache. 2002;42(Suppl 1):10\u20137.","journal-title":"Headache"},{"key":"1049_CR4","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","volume":"61","author":"J Ailani","year":"2021","unstructured":"Ailani J, Burch RC, Robbins MS, Board of Directors of the American Headache Society. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61:1021\u201339.","journal-title":"Headache"},{"key":"1049_CR5","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/head.14122","volume":"61","author":"F Sakai","year":"2021","unstructured":"Sakai F, Takeshima T, Homma G, et al. Phase\u00a02 randomized placebo-controlled study of lasmiditan for the acute treatment of migraine in Japanese patients. Headache. 2021;61:755\u201365.","journal-title":"Headache"},{"key":"1049_CR6","doi-asserted-by":"publisher","DOI":"10.1177\/03331024241258695","volume":"44","author":"R Ishii","year":"2024","unstructured":"Ishii R, Ishizuchi K, Watanabe N, et al. Efficacy and tolerability of 100\u00a0mg of lasmiditan for migraine: a multi-center, prospective observational real-world study in Japan. Cephalalgia. 2024;44:3331024241258695.","journal-title":"Cephalalgia"},{"key":"1049_CR7","doi-asserted-by":"publisher","first-page":"643","DOI":"10.3390\/neurolint16030048","volume":"16","author":"Y Shibata","year":"2024","unstructured":"Shibata Y, Sato H, Sato A, et al. Efficacy of lasmiditan as a secondary treatment for migraine attacks after unsuccessful treatment with a triptan. Neurol Int. 2024;16:643\u201352.","journal-title":"Neurol Int"},{"key":"1049_CR8","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3390\/neurolint17050062","volume":"17","author":"T Tanei","year":"2025","unstructured":"Tanei T, Yamamoto S, Maesawa S, et al. Identifying factors associated with the efficacy of lasmiditan 50\u00a0mg as an acute treatment for migraine attacks under various dosing conditions in real-world clinical practice. Neurol Int. 2025;17:62.","journal-title":"Neurol Int"},{"key":"1049_CR9","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/S0140-6736(25)00109-6","volume":"405","author":"J Versijpt","year":"2025","unstructured":"Versijpt J, Paemeleire K, Reuter U, et al. Calcitonin gene-related peptide-targeted therapy in migraine: current role and future perspectives. Lancet. 2025;405:1014\u201326.","journal-title":"Lancet"},{"key":"1049_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/neurolint18010003","volume":"18","author":"T Tanei","year":"2026","unstructured":"Tanei T, Yamashita S, Maesawa S, et al. Continuation, resumption, and withdrawal rates of CGRP-mAb treatment for migraine under real-world clinical conditions in which patients are free to choose own treatment. Neurol Int. 2026;18:3.","journal-title":"Neurol Int"},{"key":"1049_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e40190","volume":"10","author":"T Tanei","year":"2024","unstructured":"Tanei T, Fuse Y, Maesawa S, et al. Real-world clinical results of CGRP monoclonal antibody treatment for medication overuse headache of migraine without abrupt drug discontinuation and no hospitalization. Heliyon. 2024;10:e40190.","journal-title":"Heliyon"},{"key":"1049_CR12","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S0140-6736(19)31606-X","volume":"394","author":"R Croop","year":"2019","unstructured":"Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase\u00a03, double-blind, placebo-controlled trial. Lancet. 2019;394:737\u201345.","journal-title":"Lancet"},{"key":"1049_CR13","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1811090","volume":"381","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Croop R, Stock EG, et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med. 2019;381:142\u20139.","journal-title":"N Engl J Med"},{"key":"1049_CR14","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.2147\/JPR.S453806","volume":"17","author":"RB Lipton","year":"2024","unstructured":"Lipton RB, Thiry A, Morris BA, et al. Efficacy and safety of rimegepant 75\u00a0mg oral tablet, a CGRP receptor antagonist, for the acute treatment of migraine: a randomized, double-blind, placebo-controlled trial. J Pain Res. 2024;17:2431\u201341.","journal-title":"J Pain Res"},{"key":"1049_CR15","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S1474-4422(23)00126-6","volume":"22","author":"S Yu","year":"2023","unstructured":"Yu S, Kim BK, Guo A, et al. Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase\u00a03, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2023;22:476\u201384.","journal-title":"Lancet Neurol"},{"key":"1049_CR16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0140-6736(20)32544-7","volume":"397","author":"R Croop","year":"2021","unstructured":"Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase\u00a02\/3, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397:51\u201360.","journal-title":"Lancet"},{"key":"1049_CR17","doi-asserted-by":"publisher","DOI":"10.1177\/03331024251395298","volume":"45","author":"M Ashina","year":"2025","unstructured":"Ashina M, McAllister P, Gaul C, et al. Rimegepant for acute treatment of migraine in triptan-unsuitable adults: a randomized, double-blind, placebo-controlled phase\u00a04 trial. Cephalalgia. 2025;45:3331024251395298.","journal-title":"Cephalalgia"},{"key":"1049_CR18","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1111\/head.14994","volume":"65","author":"K Ikeda","year":"2025","unstructured":"Ikeda K, Matsumori Y, Kudo M, et al. Efficacy and safety of rimegepant for the acute treatment of migraine in Japan: a dose-ranging, double-blind, randomized controlled trial. Headache. 2025;65:1811\u201320.","journal-title":"Headache"},{"key":"1049_CR19","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1111\/head.14995","volume":"65","author":"S Kitamura","year":"2025","unstructured":"Kitamura S, Matsumori Y, Yamamoto T, et al. Efficacy and safety of rimegepant for the preventive treatment of migraine in Japan: a double-blind, randomized controlled trial. Headache. 2025;65:1403\u201312.","journal-title":"Headache"},{"key":"1049_CR20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s10194-024-01935-8","volume":"26","author":"LF Iannone","year":"2025","unstructured":"Iannone LF, Vaghi G, Sebastianelli G, et al. Effectiveness and tolerability of rimegepant in the acute treatment of migraine: a real-world, prospective, multicentric study (GAINER study). J Headache Pain. 2025;26:4.","journal-title":"J Headache Pain"},{"key":"1049_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-025-02197-8","volume":"26","author":"J Wang","year":"2025","unstructured":"Wang J, Jiang J, Peng S, et al. Patient-reported outcomes of rimegepant for acute and preventive treatment of migraine in China: a prospective, multicenter, real-world study. J Headache Pain. 2025;26:242.","journal-title":"J Headache Pain"},{"key":"1049_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01873-5","volume":"25","author":"Z Yang","year":"2024","unstructured":"Yang Z, Wang X, Niu M, et al. First real-world study on the effectiveness and tolerability of rimegepant for acute migraine therapy in Chinese patients. J Headache Pain. 2024;25:160.","journal-title":"J Headache Pain"},{"key":"1049_CR23","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1080\/03007995.2024.2410930","volume":"40","author":"J Ailani","year":"2024","unstructured":"Ailani J, Lewis M, Dai F, et al. Evaluation of rimegepant utilization patterns and patient characteristics among new users: a United States administrative claims-based study. Curr Med Res Opin. 2024;40:1913\u201320.","journal-title":"Curr Med Res Opin"},{"key":"1049_CR24","doi-asserted-by":"publisher","DOI":"10.1177\/03331024251352849","volume":"45","author":"SJ Tepper","year":"2025","unstructured":"Tepper SJ, Jenkins A, Henriksen C, et al. A comparison of the persistence of acute treatment with rimegepant versus oral triptans in patients with migraine: a retrospective analysis of US claims data. Cephalalgia. 2025;45:3331024251352849.","journal-title":"Cephalalgia"},{"key":"1049_CR25","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s10194-025-02028-w","volume":"26","author":"L Pellesi","year":"2025","unstructured":"Pellesi L, Do TP, Ernst MT, et al. Adoption of rimegepant in Denmark: a register-based study on uptake, prescribing patterns and initiator characteristics. J Headache Pain. 2025;26:83.","journal-title":"J Headache Pain"},{"key":"1049_CR26","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/head.15004","volume":"66","author":"N Rosen","year":"2026","unstructured":"Rosen N, Jenkins A, Hygge Blakeman K, et al. Reduction of opioid and barbiturate use following initiation of rimegepant for migraine in the United States. Headache. 2026;66:835\u201345.","journal-title":"Headache"},{"key":"1049_CR27","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s40120-024-00586-w","volume":"13","author":"T Alsaadi","year":"2024","unstructured":"Alsaadi T, Suliman R, Santos V, et al. Safety and tolerability of combining CGRP monoclonal antibodies with gepants in patients with migraine: a retrospective study. Neurol Ther. 2024;13:465\u201373.","journal-title":"Neurol Ther"},{"key":"1049_CR28","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1007\/s12325-024-03063-w","volume":"42","author":"P Eugeni","year":"2025","unstructured":"Eugeni P, Rooney ME, Saikali NP, et al. US real-world effectiveness, tolerability, and healthcare resource utilization after addition of fremanezumab for preventive treatment in patients using gepants for acute treatment of migraine: results from a retrospective chart review. Adv Ther. 2025;42:1207\u201321.","journal-title":"Adv Ther"},{"key":"1049_CR29","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018; 38: 1\u2013211.","DOI":"10.1177\/0333102417738202"},{"key":"1049_CR30","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.jpain.2015.02.007","volume":"16","author":"W Scott","year":"2015","unstructured":"Scott W, McCracken LM. Patients\u2019 impression of change following treatment for chronic pain: global, specific, a single dimension, or many? J Pain. 2015;16:518\u201326.","journal-title":"J Pain"},{"key":"1049_CR31","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"1049_CR32","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14737175.2026.2621879","volume":"26","author":"L Pellesi","year":"2026","unstructured":"Pellesi L, Scuteri D, Martelletti P. Positioning rimegepant in migraine prophylaxis: updated evidence and emerging perspectives. Expert Rev Neurother. 2026;26:315\u201323.","journal-title":"Expert Rev Neurother"},{"issue":"386","key":"1049_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-080107","volume":"18","author":"WK Karlsson","year":"2024","unstructured":"Karlsson WK, Ostinelli EG, Zhuang ZA, et al. Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysis. BMJ. 2024;18(386):e080107.","journal-title":"BMJ"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01049-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-01049-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01049-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T07:12:34Z","timestamp":1792566754000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-01049-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":33,"alternative-id":["1049"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-01049-0","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]},"assertion":[{"value":"27 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Takafumi Tanei,\u00a0Satoshi Yamashita,\u00a0Shun Yamamoto,\u00a0Shinsuke Muraoka,\u00a0Tomotaka Ishizaki,\u00a0Takahiro Suzuki,\u00a0Satoshi Shinoda,\u00a0Toshihiko Wakabayashi and\u00a0Ryuta Saito have nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Review Committee of Nagoya University Graduate School of Medicine (approval number 2025-0383). The study was conducted in accordance with the Declaration of Helsinki. Participants were aged \u2265 18 years and provided written informed consent before enrollment.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}